CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 132 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,128,000 | +39.8% | 150,000 | +72.4% | 1.16% | +12.6% |
| Q2 2023 | $2,952,962 | +64.1% | 87,031 | +74.1% | 1.03% | +73.6% |
| Q1 2023 | $1,799,000 | -63.3% | 50,000 | -54.5% | 0.59% | -69.1% |
| Q4 2022 | $4,902,700 | +118.0% | 110,000 | +37.5% | 1.92% | +206.2% |
| Q3 2022 | $2,249,000 | -54.9% | 80,000 | -56.8% | 0.63% | -70.1% |
| Q2 2022 | $4,987,000 | +17.1% | 185,000 | +48.0% | 2.10% | +208.7% |
| Q1 2022 | $4,258,000 | +10.2% | 125,000 | +25.0% | 0.68% | -51.5% |
| Q4 2021 | $3,864,000 | +78.2% | 100,000 | +149.0% | 1.40% | +156.0% |
| Q3 2021 | $2,168,000 | +29.7% | 40,154 | -19.7% | 0.55% | -8.5% |
| Q2 2021 | $1,672,000 | -37.6% | 50,000 | -61.5% | 0.60% | -34.1% |
| Q1 2021 | $2,678,000 | +103.8% | 130,000 | +73.3% | 0.91% | +30.6% |
| Q4 2020 | $1,314,000 | – | 75,000 | – | 0.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |